<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-22602-2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Development of a natural drug &quot;mimic&quot; derived from dendritic cells that activate latent HIV-1 and potentially could cure infected patients</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Currently developed LRAs are PKC pathway inducers, HDAC inhibitors or PTEN modulators. Some of these LRAs activate the virus in latently infected cells or cell lines, but treatment of patients with these LRAs does not have a positive effect on reduction of the latent viral reservoir. Dendritic cells are able to secrete a natural dLRA that reverts HIV-1 latency by other means. The activity of the dLRA is not dependent on PKC activation or the chromatin acetylation state as induced by HDAC inhibitors. With mass spectrometry and antibody depletion experiments we have identified the soluble dLRA derived from dendritic cells.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">HIV-1 can infect cells from the immune system without producing new viruses. These cells form a life-long existing viral reservoir that can not be eradicated with the current therapy. Spontaneuos virus activation of this latent HIV-1 reservoir neccesitates constant use of medication to actively suppress virus replication. This reservoir could be eradicated from pateints, if a drug is available that could activate latent HIV-1, while virus dissemmination is controlled with HAART. However, despite masive effort no effective anti-latency drug or compound is developed. We have identified a natural protein derived from dendritic cells that can activate latent HIV-1. In this project we aim to design and produce a mimic of that protein to ultimately eradicate the latent viral reservoir in patients.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">The nature of this project is fundamental research. Neverthess, those that are infected with HIV-1 could benefit by the finding.  All HIV-1 infected individuals that are on successful therapy could use the dLRA to reduce their latent viral reservoir.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">This project aims to find an effective LRA to reduce the latent HIV-1 reservoir. Current therapy in the form of HAART is effective in blocking HIV-1 replication. Treatment, however, cannot eradicate the latent HIV-1 reservoir formed in the early acute and chronic infection phase of disease progression. Eradication of the latent reservoir with an LRA combined with therapy could possibly result in cure from HIV-1. If the dLRA investigated in this project has an effect on the size of the latent reservoir, patients could be cured or the use of medication could be reduced.</narrative>
  </description>
  <participating-org ref="NL-KVK-34362777" role="4" type="80">
   <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2017-10-01" type="1"></activity-date>
  <activity-date iso-date="2018-09-01" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <location>
   <name>
    <narrative xml:lang="EN">Amsterdam</narrative>
   </name>
  </location>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Development of a natural drug &quot;mimic&quot; derived from dendritic cells that activate latent HIV-1 and potentially could cure infected patients STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2017-10-01"></period-start>
   <period-end iso-date="2018-09-01"></period-end>
   <value currency="EUR" value-date="2017-10-01">75000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-10-26"></transaction-date>
   <value currency="EUR" value-date="2017-10-26">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-10-26"></transaction-date>
   <value currency="EUR" value-date="2017-10-26">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-12-18"></transaction-date>
   <value currency="EUR" value-date="2018-12-18">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
